Navigation Links
Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
Date:3/22/2013

Dublin, Ireland (PRWEB) March 22, 2013

Research and Markets has announced the addition of Jain PharmaBiotech's new market research report "Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report" to their offering.

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.

Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions. A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries. Fifteen companies are involved in drug-eluting stents.

The cardiovascular drug delivery markets are estimated for the years 2012 to 2022 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Selected 81 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 78 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 28 tables and 7 figures.

Key Topics Covered:

Executive Summary

1. Cardiovascular Diseases

2. Methods for Drug Delivery to the Cardiovascular System

3. Cell Therapy for Cardiovascular Disorders

4. Gene Therapy for Cardiovascular Disorders

5. Drug-Eluting Stents

6. Markets for Cardiovascular Drug Delivery

7. Companies involved in Cardiovascular Drug Delivery

8. References

For more information visit Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013

Source: Jain PharmaBiotech

Research and Markets
Laura Wood, Senior Manager.
press(at)researchandmarkets(dot)com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10560022.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
3. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
6. SPX-106T Arrests Development of Atherosclerotic Plaques in Mouse Model of Cardiovascular Disease
7. Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease
8. International Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
9. Global Cardiovascular Picture Archiving and Communication Systems (CV-PACS) Industry
10. Micropharma Convenes Expert Roundtable on New Role for Probiotics in Cardiovascular Disease in time for National Cholesterol Education Month
11. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 QIAGEN N.V. (NASDAQ: QGEN ... the U.S. launch of its ipsogen ® JAK2 RGQ PCR ... and Drug Administration as a qualitative in vitro diagnostic test for the detection ... ... processed on QIAGEN,s Rotor-Gene ® Q MDx system, which is a member ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March 29, 2017) ... has been approved as an active member of the Mexican Direct Selling ... distributers and consumers in relationship marketing. This professional organization fosters loyal and fair ...
(Date:3/29/2017)... ... 29, 2017 , ... ACEA Biosciences, a privately owned biotechnology ... award to noteworthy scientists who will be presenting research using ACEA Biosciences’ technology ... awards are being given to two postdoctoral fellows studying pathogen capture by neutrophils, ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - The University ... partners Nordion, a business of Sterigenics International, and General ... has been submitted to the U.S. Nuclear Regulatory Commission ... U.S. production of molybdenum-99 (Mo-99). Once operational, production from ... of U.S. demand for Mo-99, which currently must be ...
Breaking Biology Technology:
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
Breaking Biology News(10 mins):